JP Morgan Maintains Neutral on Chemours, Lowers Price Target to $14

Benzinga · 3d ago
JP Morgan analyst Jeffrey Zekauskas maintains Chemours (NYSE:CC) with a Neutral and lowers the price target from $15 to $14.